PubMed Health⌕ Search

Biomedical subjects

I A Shevchenko

Publications and source records attributed to I A Shevchenko.

At least 19 recordsLinked to original sources

[Hypolipidemic effect of gevilon].

The drug gevilon that produces hypolipidemic effects has been clinically tested. The drug was used to treat 53 patients suffering from coronary heart disease, hypertensive disease with severe lipid metabolic disturbances. Gevilon has been found to have a hypolipidemic effect in reducing the levels of total cholesterol, beta-cholesterol, triglycerides, increasing alpha-cholesterol levels and normalizing the atherogenicity coefficient. The hypolipidemic effect of the drug is the most pronounced in Type IIb dyslipoproteinemia. Gevilon is well tolerated by patients, it can be used in combination with the drugs given in the complex therapy for coronary heart disease and hypertension.

Cyclohexanecarboxylic Acids↗

[Effects of ubinon-9, a synthetic antioxidant, on intensity of lipid peroxidation in blood platelets and plasma of patients with ischemic heart disease].

The antioxidant ubinon-9 was tested for its effects on platelet and plasma lipid peroxidation parameters in patients with acute ischemic heart diseases. The use of ubinon-9 in the multimodality therapy of patients with ischemic heart disease was shown to result in a significant decrease in lipid peroxidation intensity by enhancing superoxide dismutase activity in the platelets and plasma from the patients. Ubinon-9 equally prevented lipid peroxidation activation during enzymatic and nonenzymatic induction in the platelets of patients with unstable angina or acute myocardial infarction. Unlike a daily dose of 30 mg, 90 mg a day is a more effective dose in reducing platelet and plasma lipid peroxidation parameters. One may suggest that addition of ubinon-9 into the routine treatment regimen allows the therapy for acute ischemic heart disease to be optimize.

Adult↗